Results of Operations and Financial Condition. On August 13, 2026, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter ended June 30, 2026 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed” for…

Results of Operations and Financial Condition. On May 7, 2026, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter ended March 31, 2026 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed” for pur…

Results of Operations and Financial Condition. On March 31, 2026, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter and year ended December 31, 2025 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release attached hereto as Exhibit 99.1, shall not…

Other Events. On December 16, 2025, Kodiak Sciences Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, Evercore Group L.L.C. and UBS Securities LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the public offering, issuance and sale (the “Offering”) of 6,956,522 shares of its common stock, par value $0.0001 (“Common Stock”). The price to the p…

Results of Operations and Financial Condition. On November 13, 2025, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter ended September 30, 2025 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “file…

Results of Operations and Financial Condition. On August 13, 2025, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter ended June 30, 2025 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed” for…

Results of Operations and Financial Condition. On May 14, 2025, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter ended March 31, 2025 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed” for pu…

Results of Operations and Financial Condition. On March 27, 2025, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter and year ended December 31, 2024 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed…

Results of Operations and Financial Condition. On November 14, 2024, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter ended September 30, 2024 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “file…

Results of Operations and Financial Condition. On August 14, 2024, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter ended June 30, 2024 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed” for…

Results of Operations and Financial Condition. On May 15, 2024, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter ended March 31, 2024 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed” for pu…

Results of Operations and Financial Condition. On March 28, 2024, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter and year ended December 31, 2023 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed…

Results of Operations and Financial Condition. On November 14, 2023, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter ended September 30, 2023 and business highlights. A copy of the Company’s press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhi…

Other Events. On November 6, 2023, Kodiak announced that its Phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to severe non-proliferative diabetic retinopathy (NPDR) met its one-year primary endpoint. The Phase 3 GLOW study is a global, multi-center, randomized pivotal superiority study designed to evaluate the efficacy and safety of tarcocimab tedromer in treatment-naïve patients with moderately severe to severe NPDR. Patients are randomized to receive…

Chief Medical Officer and Chief Development Officer — Jason Ehrlich, M.D., Ph.D.: Dr. Ehrlich resigned from his roles with no named successor.

Results of Operations and Financial Condition. On August 14, 2023, Kodiak Sciences Inc. (the “Company”) issued a press release reporting the Company’s financial results for the quarter ended June 30, 2023. A copy of the Company’s press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “fil…

Results of Operations and Financial Condition. On July 24, 2023, Kodiak Sciences Inc. (“Kodiak,” or the “Company”) reported that, as of June 30, 2023 (unaudited), the Company had approximately $379 million in cash and cash equivalents. The foregoing is subject to revision based upon the Company’s quarter-end closing procedures and the completion and external review of the Company’s financial statements as of and for the quarter ended June 30, 2023.

Results of Operations and Financial Condition. On May 15, 2023, Kodiak Sciences Inc. (the “Company”) issued a press release reporting the Company’s financial results for the quarter ended March 31, 2023. A copy of the Company’s press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed…

Results of Operations and Financial Condition. On March 28, 2023, Kodiak Sciences Inc. (the “Company”) issued a press release reporting the Company’s financial results for the quarter ended December 31, 2022. A copy of the Company’s press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “…

Results of Operations and Financial Condition. On November 9, 2022, Kodiak Sciences Inc. (the “Company”) issued a press release reporting the Company’s financial results for the quarter ended September 30, 2022. A copy of the Company’s press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deeme…

Results of Operations and Financial Condition. On August 9, 2022, Kodiak Sciences Inc. (the “Company”) issued a press release reporting the Company’s financial results for the quarter ended June 30, 2022. A copy of the Company’s press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “file…

Results of Operations and Financial Condition. On May 10, 2022, Kodiak Sciences Inc. (the “Company”) issued a press release reporting the Company’s financial results for the quarter ended March 31, 2022. A copy of the Company’s press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed…

Results of Operations and Financial Condition. On March 1, 2022, Kodiak Sciences Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and year ended December 31, 2021. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The information in this Form 8-K and the attached exhibit are furnished to, but not filed with, the Securities and Exchange Commission.

Results of Operations and Financial Condition. Kodiak Sciences Inc. (the “Company”) expects that, as of December 31, 2021, its cash and cash equivalents were approximately $731.5 million.